Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1983 Nov;54(2):486–492.

Increased monocyte chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses.

B Czarnetzki
PMCID: PMC1535900  PMID: 6317241

Abstract

In vitro monocyte chemotaxis towards leukotriene B4(LTB4) and platelet activating factor (PAF) was studied with cells from 51 patients with various inflammatory dermatoses and 12 normal volunteers. Monocytes from normal subjects responded poorly to LTB4 (10(-8)-10(-12) M) and PAF (10(-6)-10(-10) M), and cells from patients with urticaria pigmentosa and vericella were even less responsive, while monocytes from patients with severe psoriasis and atopic eczema exhibited markedly enhanced chemotaxis. These changes persisted during high dose therapy with oral steroids, but returned to normal with healing of the skin lesions. Pre-incubation of monocytes with histamine, LTB4, PAF, lymphokines or sera from patients and normal controls did not result in enhanced chemotaxis of the cells. The chemotactic activity of monocytes did not correlate with that of neutrophils in the same patients (r = 0.08). Altered monocyte chemotaxis in patients with inflammatory dermatoses is therefore a reversible process that is related to the severity of the cutaneous inflammation but is not limited to a specific disease.

Full text

PDF
486

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anwar A. R., Kay B. Enhancement of human eosinophil complement receptors by pharmacologic mediators. J Immunol. 1978 Oct;121(4):1245–1250. [PubMed] [Google Scholar]
  2. Bar-Eli M., Gallily R., Cohen H. A., Wahba A. Monocyte function in psoriasis. J Invest Dermatol. 1979 Aug;73(2):147–149. doi: 10.1111/1523-1747.ep12581605. [DOI] [PubMed] [Google Scholar]
  3. Boumsell L., Meltzer M. S. Mouse mononuclear cell chemotaxis. I. Differential response of monocytes and macrophages. J Immunol. 1975 Dec;115(6):1746–1748. [PubMed] [Google Scholar]
  4. Brain S. D., Camp R. D., Dowd P. M., Black A. K., Woollard P. M., Mallet A. I., Greaves M. W. Psoriasis and leukotriene B4. Lancet. 1982 Oct 2;2(8301):762–763. doi: 10.1016/s0140-6736(82)90939-4. [DOI] [PubMed] [Google Scholar]
  5. Breathnach S. M., Carrington P., Black M. M. Neutrophil leukocyte migration in psoriasis vulgaris. J Invest Dermatol. 1981 Apr;76(4):271–274. doi: 10.1111/1523-1747.ep12526110. [DOI] [PubMed] [Google Scholar]
  6. Czarnetzki B. M., Benveniste J. Effect of 1-O-octadecyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) on leukocytes I. Analysis of the in vitro migration of human neutrophils. Chem Phys Lipids. 1981 Dec;29(4):317–326. doi: 10.1016/0009-3084(81)90065-7. [DOI] [PubMed] [Google Scholar]
  7. Czarnetzki B. M., Grabbe J. Biological and chemical characterization of eosinophil chemotactic factors from human leukocytes. Agents Actions Suppl. 1983;12:204–216. doi: 10.1007/978-3-0348-9352-7_12. [DOI] [PubMed] [Google Scholar]
  8. Czarnetzki B. M., König W., Lichtenstein L. M. Eosinophil chemotactic factor (ECF). I. Release from polymorphonuclear leukocytes by the calcium ionophore A23187. J Immunol. 1976 Jul;117(1):229–234. [PubMed] [Google Scholar]
  9. Demopoulos C. A., Pinckard R. N., Hanahan D. J. Platelet-activating factor. Evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). J Biol Chem. 1979 Oct 10;254(19):9355–9358. [PubMed] [Google Scholar]
  10. Falk W., Tomisawa S., Klimetzek V., Meltzer M. S. Chemotactic activity of bone marrow-derived macrophages changes with time in culture. Infect Immun. 1981 Aug;33(2):629–631. doi: 10.1128/iai.33.2.629-631.1981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Furukawa C. T., Altman L. C. Defective monocyte and polymorphonuclear leukocyte chemotaxis in atopic disease. J Allergy Clin Immunol. 1978 May;61(5):288–293. doi: 10.1016/0091-6749(78)90049-0. [DOI] [PubMed] [Google Scholar]
  12. Goetzl E. J., Derian C. K., Tauber A. I., Valone F. H. Novel effects of 1-O-hexadecyl-2-acyl-sn-glycero-3-phosphorycholine mediators on human leukocyte function: delineation of the specific roles of the acyl substituents. Biochem Biophys Res Commun. 1980 Jun 16;94(3):881–888. doi: 10.1016/0006-291x(80)91317-0. [DOI] [PubMed] [Google Scholar]
  13. Goetzl E. J. Mediators of immediate hypersensitivity derived from arachidonic acid. N Engl J Med. 1980 Oct 2;303(14):822–825. doi: 10.1056/NEJM198010023031421. [DOI] [PubMed] [Google Scholar]
  14. Grabbe J., Czarnetzki B. M., Mardin M. Chemotactic leukotrienes in psoriasis. Lancet. 1982 Dec 25;2(8313):1464–1464. doi: 10.1016/s0140-6736(82)91365-4. [DOI] [PubMed] [Google Scholar]
  15. Krueger G. G., Jederberg W. W., Ogden B. E., Reese D. L. Inflammatory and immune cell function in psoriasis: II. Monocyte function, lymphokine production. J Invest Dermatol. 1978 Sep;71(3):195–201. doi: 10.1111/1523-1747.ep12547138. [DOI] [PubMed] [Google Scholar]
  16. Mier P. D., Gommans J. M., Roelfzema H. On the aetiology of psoriasis. Br J Dermatol. 1980 Oct;103(4):457–460. doi: 10.1111/j.1365-2133.1980.tb07272.x. [DOI] [PubMed] [Google Scholar]
  17. Molin L., Reizenstein P. Hematological changes in psoriasis. Secondary anemia, XVIII. Acta Derm Venereol. 1974;54(6):465–469. [PubMed] [Google Scholar]
  18. Smith M. J., Ford-Hutchinson A. W., Bray M. A. Leukotriene B: a potential mediator of inflammation. J Pharm Pharmacol. 1980 Jul;32(7):517–518. doi: 10.1111/j.2042-7158.1980.tb12985.x. [DOI] [PubMed] [Google Scholar]
  19. Snyderman R., Rogers E., Buckley R. H. Abnormalities of leukotaxis in atopic dermatitis. J Allergy Clin Immunol. 1977 Aug;60(2):121–126. doi: 10.1016/0091-6749(77)90037-9. [DOI] [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES